ArticleInternational journal of molecular sciences2022

Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.

Shujie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.